• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of January 25

Video

Here are the top 5 biosimilar articles for the week of January 25, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 25, 2021.

Number 5: Charles Bennett, MD, PhD, a hematologist, oncologist, and professor at the University of South Carolina, explained the many sticking points that prevent biosimilar savings.

Number 4: It took Henlius years to get a rituximab biosimilar approved in China. Now, that process could be cut in half, owing to significant regulatory reforms.

Number 3: An attempt by investigators to understand whether regulatory and scientific sources are consistent with each other in their reporting of quality attributes for biosimilars has demonstrated general conformance between these 2 sources of biosimilar information.

Number 2: The CEO of Prestige Biopharma said that biosimilars will be the cornerstone for a leap into biologics development and commercialization. Meanwhile, Innovent Biologics reaches a marketing agreement.

Number 1: Coherus BioSciences CEO Dennis M. Lanfear discusses the company's biosimilar marketing prospects in 2021.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
Here are the top 5 biosimilar articles for the week of April 15, 2024.
The Top 5 Biosimilars Articles for the Week of April 8, 2024.
Ha Kung Wong, JD.
Related Content
© 2024 MJH Life Sciences

All rights reserved.